COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry
暂无分享,去创建一个
S. Nadalin | F. Hanses | S. Dolff | S. Borgmann | R. Strauss | M. Lilienfeld-Toal | B. Grüner | N. Isberner | G. Beutel | M. Rüthrich | C. Piepel | K. Wille | M. Schons | J. Lanznaster | L. Tometten | C. Gießen-Jung | J. J. Vehreschild | Uta Merle | Annika Classen | Philipp Köhler | J. Schneider | Kai Wille | Philipp Köhler | Annika Y. Classen
[1] J. Nattermann,et al. First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)” , 2020, Infection.
[2] C. Miething,et al. Covid‐19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany , 2020, Cancer medicine.
[3] H. Wildiers,et al. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis , 2020, ESMO Open.
[4] E. Wulff-Burchfield,et al. Sex-bias in COVID-19-associated illness severity and mortality in cancer patients: A systematic review and meta-analysis , 2020, EClinicalMedicine.
[5] D. Kerr,et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study , 2020, The Lancet Oncology.
[6] H. Einsele,et al. Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. , 2020, Haematologica.
[7] A. Sanyaolu,et al. Comorbidity and its Impact on Patients with COVID-19 , 2020, SN Comprehensive Clinical Medicine.
[8] N. Joharatnam-Hogan,et al. COVID-19 cancer conundrum—evidence driving decisions or the lack of it? , 2020, BMC Medicine.
[9] Zhiquan Hu,et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.
[10] Alokkumar Jha,et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.
[11] D. Kerr,et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.
[12] S. Kalnicki,et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.
[13] M. Santillana,et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.
[14] R. Gale,et al. COVID-19 in persons with haematological cancers , 2020, Leukemia.
[15] Eun Ji Kim,et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.
[16] C. Wang,et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.
[17] Wei Wang,et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.
[18] H. Rothan,et al. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.
[19] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[20] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[21] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[22] P. Ferdinande,et al. The variability of critical care bed numbers in Europe , 2012, Intensive Care Medicine.